BioAge Labs, Inc. Class Action Lawsuit - BIOA

Company: BioAge Labs, Inc. (NASDAQ: BIOA)
Lead Plaintiff Deadline: March 10, 2025 (Expired)
Class Definition: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.

Expired

Lead Plaintiff Deadline

Mar 10, 2025

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

Eligibility

In order to be eligible to join the BIOA class action lawsuit, you must have incurred a loss on shares of BioAge purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP